MOD-4023 (Long-Lasting Human Growth Hormone (hGH)) Study in Growth Hormone Deficient Adults (GHDA)
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This study aims to assess the safety, tolerability and Pharmacokinetics/ Pharmacodynamics
(PK/PD) profile of three doses of MOD-4023 on a weekly regime and one dose on an
every-other-week regime administered for a period of 4 weeks in Growth Hormone Deficient
Adult (GHDA) patients who previously were on a stable r-hGH treatment. An additional
extension period of 16 weeks once-weekly administration of MOD-4023 aims to confirm the dose
selection for future trials.